December 2021

Clinical results from the UK Optimum/Muknine Trial

Latest results from the UK Optimum Trial are presented by Dr. Martin F. Kaiser, UK, in this MEDtalk. Findings suggest patients with diagnosed multiple myeloma (NDMM) and patients with primary plasma cell leukemia (pPCL), to benefit significantly in progression free survival at 18 months when treated in OPTIMUM (5-drug combination (Dara-CVRd) followed by stem cell transplantation and 4-drug combination (Dara-VRd)), compared a digital comparator arm using molecularly matched patients from another study (NCRI Myeloma XI/XI+ trial (NCT01554852)).

For more details read abstract: https://ash.confex.com/ash/2021/webprogram/Paper144990.html

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Register
Already a user? Login

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Clinical results from the UK Optimum/Muknine Trial

Get access

Asiaan liittyvä sisältö